Leerink analyst Joseph Schwartz raised his price target for Tobira Therapeutics (TBRA) to $45 from $15 following the release of abstracts for the American Academy for the Study of Liver Diseases Meeting, with the company providing additional results from the CENTAUR Phase 2b trial of Cenicriviroc for the treatment of non-alcoholic steatohepatitis with liver fibrosis. The analyst believes Tobira is a "pioneer" in the nonalcoholic steatohepatitis development space, and notes that the current stock price somewhat undervalues the acquisition terms based on the most probable outcomes and contingent value rights' conditions from Allergan (AGN). Schwartz reiterates an Outperform rating on Tobira's shares.